BrainsWay Ltd. (NASDAQ:BWAY) Sees Significant Increase in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 49,600 shares, an increase of 81.0% from the December 15th total of 27,400 shares. Based on an average trading volume of 76,700 shares, the short-interest ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

BWAY has been the topic of several recent research reports. Northland Securities raised their price target on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research note on Monday, December 23rd.

BrainsWay Trading Up 5.2 %

Shares of BrainsWay stock traded up $0.49 during trading hours on Tuesday, reaching $9.92. 90,391 shares of the company’s stock were exchanged, compared to its average volume of 45,988. The stock has a market cap of $186.62 million, a P/E ratio of 99.21 and a beta of 1.23. The company has a 50 day moving average of $9.71 and a two-hundred day moving average of $8.58. BrainsWay has a fifty-two week low of $4.61 and a fifty-two week high of $10.98.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The business had revenue of $10.50 million for the quarter, compared to the consensus estimate of $10.07 million. During the same period in the previous year, the company earned ($0.01) earnings per share. As a group, analysts expect that BrainsWay will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BrainsWay

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in shares of BrainsWay by 316.3% during the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after purchasing an additional 11,221 shares during the period. Good Life Advisors LLC grew its holdings in BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after buying an additional 22,080 shares in the last quarter. Finally, Rhumbline Advisers increased its position in BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after buying an additional 1,695 shares during the period. 30.11% of the stock is owned by institutional investors.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.